Creating new drugs to block a protein that helps prostate cancer grow
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
This study is working on new treatments for advanced prostate cancer by finding ways to block a protein called FABP5 that helps cancer grow, with the hope of offering better options for patients whose cancer hasn't responded to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-10775710 on NIH RePORTER |
What this research studies
This research focuses on developing new inhibitors that target fatty acid binding protein 5 (FABP5), which plays a crucial role in the progression of metastatic prostate cancer. The approach involves understanding how FABP5 facilitates the transport of lipids that promote tumor growth and finding ways to block its function. By creating potent and selective inhibitors, the research aims to provide a novel therapeutic option for patients with advanced prostate cancer that has become resistant to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer, particularly those whose cancer has become resistant to standard therapies.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively combat metastatic prostate cancer.
How similar studies have performed: While the approach of targeting FABP5 is promising, it is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Ojima, Iwao — State University New York Stony Brook
- Study coordinator: Ojima, Iwao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.